Cellular Biomedicine Group Hosts Open House Titled "Advancing Solutions to Cancerous and Degenerative Straits" on April 17, 2...
April 08 2015 - 12:01PM
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the
"Company"), a biomedicine firm engaged in the development of
effective treatments for degenerative and cancerous diseases, today
announced the Company will host an open house titled "Advancing
Solutions to Cancerous and Degenerative Straits" following the
China BIO conference in Shanghai on April 17, 2015 beginning at
8:30 a.m. located at the Company's facility at 333 Guiping Road,
Building 1, Caohejing High Technology Park, Shanghai, China.
During this forum, CBMG's senior management team will discuss
the Company's immuno-oncology cell therapy platform and clinical
programs, including a comprehensive review of Phase I data on
Chimeric Antigen Receptor T Cell (CAR-T) CD19 and CD20 that was
previously released on March 25, 2015. In addition, there will also
be a comprehensive review of the Phase IIb interim data on ReJoinTM
human adipose-derived mesenchymal progenitor cell (haMPC) therapy
for the treatment of Knee Osteoarthritis that was released on March
25, 2015. The event will feature presentations and question and
answer sessions involving the principals leading CBMG's multiple
ongoing and planned clinical studies. The session will be followed
by a tour of CBMG's GMP facility and state-of-the-art research
laboratories. "We look forward to reaffirming with our investors
and strategic partners the business model we have created to become
a world-class biotechnology firm focused on providing solutions to
large unmet medical needs," commented Dr. William (Wei) Cao, Chief
Executive Officer of Cellular Biomedicine Group.
We have crafted an agenda based on feedback from our investors
that will deliver the following key messages:
- Cellular Biomedicine Group is a clinical stage independent
company focused on cell therapy platforms for various cancers and
knee osteoarthritis
- The Company is fully committed to the highest standard of
corporate governance as well as transparency and fair and timely
disclosure in full compliance with applicable law and SEC
regulations
- The Company engages with experts who understand the stem cell
and immuno-oncology cell therapy platforms
- Cellular Biomedicine Group has projected milestones in 2015
with the release of Phase I clinical data on CAR-T constructs
targeting CD30-positive Hodgkin's lymphoma and EGFR-HER1-positive
advanced lung cancer to be presented at the European Cancer
Congress in September and 48-week Phase II data on ReJoinTM in Q4,
2015
CLINICAL TRIALS
Please access the clinical trial details registered with the
U.S. National Institute of Health (NIH) here:
- ReJoinTM for KOA NCT02162693
- CAR-T CD19 for Acute Lymphocytic Leukemia (B-cell ALL)
NCT01864889
- CAR-T CD20 for Advanced Diffuse Large B Cell Lymphoma
NCT01735604
- CAR-T CD30 for Hodgkin's lymphoma NCT02259556
- EGFR-HER1 for advanced lung cancer NCT01869166
ATTENDANCE AND PARTICIPATION
To register to attend the event, please email
sarah.kelly@cellbiomedgroup.com.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell
therapies for the treatment of certain degenerative diseases and
cancers. Our developmental stem cell, progenitor cell, and immune
cell projects are the result of research and development by
scientists and doctors from China and the United States. Our
flagship GMP facility in China, consisting of eight independent
cell production lines, is designed, certified and managed according
to U.S. standards. To learn more about CBMG, please visit:
www.cellbiomedgroup.com
Forward-Looking Statements
Statements in this press release relating to plans, strategies,
trends, specific activities or investments, and other statements
that are not descriptions of historical facts may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include, but are not
limited to, risk factors inherent in doing business.
Forward-looking statements may be identified by terms such as
"may," "will," "expects," "plans," "intends," "estimates,"
"potential," or "continue," or similar terms or the negative of
these terms. Although CBMG believes the expectations reflected in
the forward-looking statements are reasonable, they cannot
guarantee that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to
update these forward-looking statements other than as required by
law.
CONTACT: Sarah Kelly
Director of Corporate Communications, CBMG
+1 650 566-5064
sarah.kelly@cellbiomedgroup.com
Vivian Chen
Managing Director Investor Relations, Grayling
+1 347 481-3711
vivian.chen@grayling.com
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Apr 2023 to Apr 2024